BRAF and melanoma: Moreover, clinical studies have reported that patients with melanoma carrying BRAF mutation and PTEN inactivation showed a trend for shorter median progression-free survival (PFS) on BRAF inhibitor-targeted therapy than patients with melanoma having wild-type PTEN19,20.